3-Indoleacetonitrile

Name: 3-Indoleacetonitrile
Brand: MedChemExpress
SKU: HY-Y0136
Rating: 4.5 (1 reviews)

Cat. No.: HY-Y0136 Purity: 99.92%: Data Sheet
SDS

COA
Handling Instructions
FAQs
Technical Support

3-Indoleacetonitrile is an indole derivative with anti-influenza activity. 3-Indoleacetonitrile is a plant hormone produced by cruxiferous vegetables. 3-Indoleacetonitrile exerts profound antiviral activity against a broad spectrum of influenza A viruses, HSV-1 and VSV viruses in vitro. 3-Indoleacetonitrile diminishes lung virus titers and alleviates lung lesions in vivo. 3-Indoleacetonitrile induces an increase in mitochondrial antiviral-signaling (MAVS) protein levels. 3-Indoleacetonitrile can be used in research for combating viral infections including COVID-19, HSV-1, and VSV.

For research use only. We do not sell to patients.

3-Indoleacetonitrile Chemical Structure

CAS No. : 771-51-7

Size	Stock	Quantity

Free Sample (0.1 - 0.5 mg)	Apply Now
Solid or liquid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid or liquid
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	Get quote
5 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of 3-Indoleacetonitrile:

3-Indoleacetonitrile (Standard) Get quote

1 Publications Citing Use of MCE 3-Indoleacetonitrile

•Phytomedicine. 2024 May 28:131:155758. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HSV Isoform Specific Products:

View All Isoforms

HSV-1 HSV-2 HSV

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Human Endogenous Metabolite

In Vitro

3-Indoleacetonitrile (0-1.5 mM, 24 h) results in significant decrease in GFP fluorescence and inhibited viral proliferation in A549 cells infected with H5N6-GFP virus at an MOI of 0.005^[1].
3-Indoleacetonitrile (350 μM, 12-36 h) reduces PR8 PB2 and NP protein levels in A549 cells compared to Arbidol^[1].
3-Indoleacetonitrile (350 μM, 24 h) exerts potent anti-influenza activity in MDCK cells^[1].
3-Indoleacetonitrile (0-350 μM, 9 h) reduces viral NP and PB2 proteins dose-dependently in A549 infected with H5N6^[1].
3-Indoleacetonitrile (0-350 μM, 9 h) impairs PB2 and NP synthesis of PR8, H1N1, H3N2, and California09 H1N1 strains infected A549 cells^[1].
3-Indoleacetonitrile (320-640 μM, 24 h) significantly decreases the densities of GFP fluorescence of VSV or HSV-1 and inhibits viral proliferation in Vero E6 and 293T cells^[2].
3-Indoleacetonitrile (0-1.28 mM, 24 h) has EC₅₀ of 86.38 μM in Caco-2 and EC₅₀ of 38.79 μM Huh7.0 cells infected with SARS-CoV-2 at MOI of 1^[2].
3-Indoleacetonitrile (0-640 μM, 12 h) activates the IFN signaling pathway in 293T cells co-transfected with pGL4-IFN-β and pRL-TK^[2].
3-Indoleacetonitrile (680 μM, 0-24 h) results in dramatically higher ISRE- and NF-κB –responsive luciferase activity in 293T cells^[2].
3-Indoleacetonitrile (0-50 μM, 12 h) induces a dose-dependent increase in LC3-II and SQSTM1 protein levels in Vero E6 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	Vero E6 or 293T cells
Concentration:	320 μM (for Vero E6) or 640 μM (for 293T)
Incubation Time:	24 h
Result:	Showed unapparent cytotoxicity in both cell lines up to indicated concentrations.

Immunofluorescence^[2]

Cell Line:	Caco-2, Huh7.0
Concentration:	80, 160, 320, 640, and 1280 μM for Caco-2 cells; 20, 40, 80, 160, and 320 μM for Huh7.0 cells
Incubation Time:	24 h
Result:	Showed obvious decrease in densities of FITC fluorescence in both cell lines.

In Vivo

3-Indoleacetonitrile (0.2-20 mg/kg, tail i.v., 10 d) does not alter body weights and health conditions of female BALB/c mice^[1].
3-Indoleacetonitrile (20 mg/kg, tail i.v., two doses with the second dose administered 1/3/5/7/9 dpi.) results in less weight loss and increased survival rate of H5N6-infected mice to 45.45% and PR8-infected mice to 50%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Eight-week-old SPF BALB/c female mice inoculated with 50 μL of 2 LD₅₀ H5N6 viruses^[1]
Dosage:	20 mg/kg
Administration:	Intravenous injection (i.v.) on tail, two doses with the second dose administered 1/3/5/7/9 dpi.
Result:	Significantly reduced the viral load in the lungs of mice. Reduced lung lesions caused by viral infection. Was able to restrict influenza replication in mice.

Molecular Weight

156.19

Formula

C₁₀H₈N₂

CAS No.

771-51-7

Appearance

<33°C Solid,>36°C Liquid

Color

Light yellow to brown

SMILES

N#CCC1=CNC2=C1C=CC=C2

Structure Classification

Others

Initial Source

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (640.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 1 mg/mL (6.40 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	6.4025 mL	32.0123 mL	64.0246 mL
5 mM	1.2805 mL	6.4025 mL	12.8049 mL
10 mM	0.6402 mL	3.2012 mL	6.4025 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (16.01 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (16.01 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (16.01 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.92%

Select Batch:

Data Sheet (281 KB) SDS (480 KB)

COA (251 KB) HNMR (235 KB) LCMS (97 KB)

Handling Instructions (2659 KB)

References

[1]. Zhao, X., et al., (2021). 3-Indoleacetonitrile Is Highly Effective in Treating Influenza A Virus Infection In Vitro and In Vivo. Viruses, 13(8), 1433. [Content Brief]

[2]. Hui, X., et al., (2023). In vitro and in vivo effects of 3-indoleacetonitrile-A potential new broad-spectrum therapeutic agent for SARS-CoV-2 infection. Antiviral research, 209, 105465. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	6.4025 mL	32.0123 mL	64.0246 mL	160.0615 mL
H₂O / DMSO	5 mM	1.2805 mL	6.4025 mL	12.8049 mL	32.0123 mL
DMSO	10 mM	0.6402 mL	3.2012 mL	6.4025 mL	16.0061 mL
	15 mM	0.4268 mL	2.1342 mL	4.2683 mL	10.6708 mL
	20 mM	0.3201 mL	1.6006 mL	3.2012 mL	8.0031 mL
	25 mM	0.2561 mL	1.2805 mL	2.5610 mL	6.4025 mL
	30 mM	0.2134 mL	1.0671 mL	2.1342 mL	5.3354 mL
	40 mM	0.1601 mL	0.8003 mL	1.6006 mL	4.0015 mL
	50 mM	0.1280 mL	0.6402 mL	1.2805 mL	3.2012 mL
	60 mM	0.1067 mL	0.5335 mL	1.0671 mL	2.6677 mL
	80 mM	0.0800 mL	0.4002 mL	0.8003 mL	2.0008 mL
	100 mM	0.0640 mL	0.3201 mL	0.6402 mL	1.6006 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.